Compare Simon Property Group Inc (SPG) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Simon Property Group Inc vs Twist Bioscience Corp — how do they compare? Simon Property Group Inc trades at $200.15 (market cap $64.59B), while Twist Bioscience Corp trades at $160.94 (market cap $10.08B). The key difference: Simon Property Group Inc is far larger — about 6.4× Twist Bioscience Corp's market cap, and Simon Property Group Inc pays a 4.46% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Simon Property Group Inc for 99 Days and Twist Bioscience Corp for 27 Days on average.
| SPG | TWST | |
|---|---|---|
Market Cap | $64.59B | $10.08B |
Volume | 1,093,907 | 4,229,037 |
Sector | Real Estate | Health |
52-Week High | $236.70 | $205.00 |
52-Week Low | $173.35 | $25.45 |
Typical Hold Time | 99 Days | 27 Days |
Enterprise Value | $93.03B | $10.01B |
Dividend Yield | 4.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPG trades at $199.96, up 1.2% over the past day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong 2025 results with revenue of $6.36B and net income of $4.63B, though Q2 2026 earnings missed expectations. Analyst consensus is a $222.90 price target with 42% buy ratings. Recent news highlights strong leasing demand and a new media network launch, while rising bond yields pose a sector headwind.
SPG offers value with a P/E of 14.09 and robust profitability margins, but faces risks from high leverage with $24.21B in long-term debt and sensitivity to interest rates. The stock's current price below the consensus target suggests potential upside if operational strength continues, though investors should weigh debt maturities and economic cyclicality.
Twist Bioscience (TWST) trades at $162.43, up 4.36% today, showing strong momentum despite recent earnings misses. The stock maintains a bullish technical signal with RSI at 29.02 indicating potential oversold conditions. Fundamentally, revenue growth continues (2025: $377M, 2026: $432M projected) but profitability remains elusive with negative margins. Recent partnership with Eli Lilly's TuneLab platform highlights strategic positioning in AI-driven drug discovery.
While analyst consensus favors Buy (73%), the stock trades above the $145.20 target, suggesting limited near-term upside. Key risks include persistent cash burn (-$44M net CF in 2025) and high valuation multiples (P/S: 21.5). The AI biotech partnership provides growth catalyst potential, but profitability timeline remains uncertain for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Simon Property Group Inc
Simon Property Group is the second- largest real estate investment trust in the United States. Its portfolio includes an interest in 207 properties: 119 traditional malls, 69 premium outlets, 14 Mills centers (a combination of a traditional mall, outlet center, and big-box retailers), six lifestyle centers, and five other retail properties. Simon's portfolio averaged $693 in sales per square foot over the 12 months prior to the pandemic. The company also owns a 21% interest in Klepierre, a European retail company with investments in shopping centers in 16 countries, and joint venture interests in 33 premium outlets across 11 countries.
Read more on SPG →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
